Krisztian Homicsko

Lausanne University Hospital

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Cancer Biology Cancer Biology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

John Prior

Professor and Head of Department

Lausanne University Hospital

SWITZERLAND

View details

Ilaria Marinoni

University of Bern

SWITZERLAND

View details

Gioele La Manno

Karolinska Institutet

SWEDEN

View details

Bettina Bisig

Lausanne University Hospital

SWITZERLAND

View details

Olivier Michielin

Geneva University Hospitals (HUG)

SWITZERLAND

View details

LANA E. KANDALAFT

Associate Professor

University of Lausanne

SWITZERLAND

View details

F. Kuonen

SWITZERLAND

View details

Michel Cuendet

SIB Swiss Institute of Bioinformatics

SWITZERLAND

View details

Erica Tavazzi

University of Padova

ITALY

View details

Jonathan Paz Montoya

EPFL (École Polytechnique Fédérale de Lausanne)

SWITZERLAND

View details

Iacovos Michael

Assistant Professor

University of Toronto

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Krisztian Homicsko

Research Interests

Explore related searches

Contact this professor

Articles (11)

Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma

Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma

Sphingolipids control dermal fibroblast heterogeneity

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer.

Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Turning tumors from cold to inflamed to improve immunotherapy response

Ovarian cancer with high-level focal <i>ERBB2</i> amplification responds to trastuzumab and pertuzumab.

Collaborators (11)

John Prior

Ilaria Marinoni

Gioele La Manno

Bettina Bisig

Olivier Michielin

LANA E. KANDALAFT

F. Kuonen

Michel Cuendet

Erica Tavazzi

Jonathan Paz Montoya

Iacovos Michael

Make your next move.